Hello and welcome to this video series sponsored by Bayer in which we are going to explore Eylea 8 mg for the treatment of age-related macular degeneration and diabetic macular edema. I am Professor ...

"Millions of packages moved away from SurePost and the United States Postal Service and returned to UPS package cars this month, now being sorted and delivered by hardworking UPS Teamsters." ...

Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 ...

The introduction of the first-generation anti-VEGF drugs—Macugen (pegaptanib), Eylea (aflibercept), Lucentis (ranibizumab), and Avastin (bevacizumab)—has since been followed by longer-lasting agents ...

The company’s Eylea product line, particularly the Eylea HD, has promising developments with a pre-filled syringe application on track for a mid-2025 US launch. This positions it to compete effe ...

Earlier on Monday, Regeneron shared preliminary results from the fourth quarter that showed Eylea HD generated just $305 million in the U.S. It was a stunning drop-off from the $392 million the ...

Regeneron’s lead drug, Eylea (aflibercept), is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications. To counter the ongoing decline in Eylea sales ...

Total Eylea sales were $1.495 billion in the final quarter of 2024, coming in 1% ahead of the $1.478 billion expectation, according to the BMO note. Meanwhile, sales of the drug’s more recently ...

Monthly in-depth briefings on Boardroom appointments and M&A news. Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable ...

Primarily, the lower-than-expected sales figures for Eylea’s high dose in the fourth quarter raised concerns, as revenues fell short of both his and market consensus estimates. This ...

The European Commission’s decision on approval is expected in the second half of January 2025. Eylea ® (Aflibercept) is used to treat neovascular age-related macular degeneration (nAMD) and other ...